계명대학교 의학도서관 Repository

Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms

Metadata Downloads
Affiliated Author(s)
하정숙
Alternative Author(s)
Ha, Jung Sook
Journal Title
Annals of Laboratory Medicine
ISSN
2234-3806
Issued Date
2015
Abstract
Background: Calreticulin (CALR) mutations were recently discovered in patients with myeloproliferative neoplasms (MPNs). We studied the frequency and type of CALR mutations and their hematological characteristics.
Methods: A total of 168 MPN patients (36 polycythemia vera [PV], 114 essential thrombocythemia [ET], and 18 primary myelofibrosis [PMF] cases) were included in the study. CALR mutation was analyzed by the direct sequencing method.
Results: CALR mutations were detected in 21.9% of ET and 16.7% of PMF patients, which accounted for 58.5% and 33.3% of ET and PMF patients without Janus kinase 2 (JAK2) or myeloproliferative leukemia virus oncogenes (MPL) mutations, respectively. A total of five types of mutation were detected, among which, L367fs*46 (53.6%) and K385fs*47 (35.7%) were found to be the most common. ET patients with CALR mutation had lower leukocyte counts and ages compared with JAK2-mutated ET patients.
Conclusion: Genotyping for CALR could be a useful diagnostic tool for JAK2-or MPL-negative ET or PMF patients. CALR mutation may be a distinct disease group, with different hematological characteristics than that of JAK2-positive patients.
Key Words: Calreticulin, JAK2, MPL, Myeloproliferative neoplasm
Department
Dept. of Laboratory Medicine (진단검사의학)
Publisher
School of Medicine
Citation
Jung-Sook Ha and Yu-Kyung Kim. (2015). Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms. Annals of Laboratory Medicine, 35(1), 22–27. doi: 10.3343/alm.2015.35.1.22
Type
Article
ISSN
2234-3806
DOI
10.3343/alm.2015.35.1.22
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35007
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.